Moderna's Melanoma Data Rewrites the Narrative — But the Stock Has Already Run Ahead of Itself

Moderna's first successful Phase 3 mRNA cancer vaccine trial with Merck triggers analyst upgrades and a massive stock rally, but valuation concerns linger.

The numbers are staggering by any measure. A stock that bottomed out at €19.36 barely three months ago now trades near €135 — a 597 percent surge that has turned Moderna into one of the most talked-about names in biotech this summer. But the real story isn't the share price. It's what triggered the move: the first successful Phase 3 trial for an mRNA-based cancer vaccine, a result that finally answers the question that has dogged the company since the pandemic faded.

A Watershed Moment With a Clinical Backbone

On August 19, Moderna and partner Merck announced that their personalized mRNA cancer candidate, intismeran autogene, hit its primary endpoint in the INTerpath-001 study. The trial, which enrolled 1,137 patients with resected stage IIB-IV melanoma, showed the vaccine — administered alongside Merck's blockbuster immunotherapy Keytruda — extended both relapse-free survival and survival without distant metastases. It marks the first late-stage success for an mRNA cancer vaccine in history.

For a company whose identity remains welded to COVID-19, the result carries weight beyond the data itself. It validates the underlying platform's potential well beyond infectious disease — a point Bank of America's Alec Stranahan drove home when he called the findings a "watershed moment" that allows Moderna to distance itself from its pandemic-era dependence. BofA lifted its rating from underperform to neutral and quadrupled its price target from $40 to $170 in a single stroke.

The analyst response was unusually broad. Goldman Sachs raised its target from $67 to $120 while holding at neutral. Morgan Stanley moved to $89 from $39, keeping an equalweight stance. UBS and Jefferies both set targets at $150, Piper Sandler went to $167 with an overweight rating, and William Blair upgraded to outperform. Even the skeptics conceded ground: JPMorgan stayed underweight but lifted its target from $40 to $77, while Barclays — the most recent mover on August 24 — raised its objective from $48 to $125 while maintaining equal weight.

The Cautionary Voices in the Chorus

Not everyone is prepared to extrapolate a platform revolution from a single trial. Wolfe Research, which upgraded the stock from underperform to peer perform the following day, notably declined to issue a new price target — acknowledging the study de-risks the platform without endorsing the current valuation.

Barclays' Eliana Merle struck a similar note, arguing the share price already embeds "significant credit" for intismeran's potential across multiple tumor types. The opportunity is real, she suggested — but it may already be priced in.

That tension between scientific breakthrough and market reality sits at the heart of Moderna's current predicament. The stock has climbed roughly 175 percent in 30 days and trades 115 percent above its 50-day moving average. Technical indicators flash overheated: the relative strength index sits at 72.1, and annualized volatility has reached an extraordinary 517 percent. A pullback was inevitable — and indeed, the shares recently closed at €135.86, about 9.2 percent below the 52-week high set just weeks earlier.

The Operating Reality Behind the Rally

The fundamental picture is more sobering. Moderna reported second-quarter revenue of just $145 million with a GAAP net loss of $782 million. The company has trimmed cash costs by 10 percent and cut its 2026 revenue forecast to roughly $4 billion. Its product portfolio is gradually diversifying — mFLUSIVA, a seasonal flu shot, became the company's fifth approved product in early August — but the pipeline has hit snags. A Phase 3 norovirus vaccine trial failed to meet the statistical criteria for early success in July, forcing the recruitment of an additional cohort.

What Comes Next

The next one to two years will be decisive. Merck and Moderna expect additional readouts in bladder, kidney, pancreatic, and gastric cancers — indications that would dramatically expand the platform's addressable market if results prove positive. Melanoma has demonstrated the principle works; the question is whether it translates across tumor types.

The sheer dispersion in price targets — ranging from $77 to $170 — underscores how uncertain that translation remains. Even the experts can't agree on how much of this promise is already reflected in the share price. For investors watching from the sidelines, the near-term trajectory matters less than the upcoming trial readouts. Those results will determine whether Moderna becomes a durable growth story or a cautionary tale about a market that got ahead of the science.